A B Sousa, J P Fernandes, I Costa, G Ferreira, O Nunes, P Ribeiro, A Neves, E Cruz, F Aveiro, A S Rodrigues, M Bernardo, A Conduto, A J Gonçalves, A Monteiro, M Sousa, V H Soares, J Veiga, J Gouveia
{"title":"Granulocyte-macrophage colony-stimulating factor in post-remission therapy of acute myeloid leukemia.","authors":"A B Sousa, J P Fernandes, I Costa, G Ferreira, O Nunes, P Ribeiro, A Neves, E Cruz, F Aveiro, A S Rodrigues, M Bernardo, A Conduto, A J Gonçalves, A Monteiro, M Sousa, V H Soares, J Veiga, J Gouveia","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The impact on occult leukemia of GM-CSF as a sensitizing agent has not been studied. We treated 41 adult patients with de novo acute myeloid leukemia, 25 of whom achieved complete remission and were given 1 to 3 post-remission courses, each course including GM-CSF begun 4 days prior to chemotherapy and given until day 3. After a median follow-up of 32 months, the probability of remaining in continuous complete remission was 17% at 46 months. GM-CSF in this setting was not associated with an improved outcome, arguing against a priming effect.</p>","PeriodicalId":73231,"journal":{"name":"Hematology and cell therapy","volume":"40 2","pages":"63-6"},"PeriodicalIF":0.0000,"publicationDate":"1998-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology and cell therapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The impact on occult leukemia of GM-CSF as a sensitizing agent has not been studied. We treated 41 adult patients with de novo acute myeloid leukemia, 25 of whom achieved complete remission and were given 1 to 3 post-remission courses, each course including GM-CSF begun 4 days prior to chemotherapy and given until day 3. After a median follow-up of 32 months, the probability of remaining in continuous complete remission was 17% at 46 months. GM-CSF in this setting was not associated with an improved outcome, arguing against a priming effect.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
